Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix (NBTX) announced a virtual event titled 'Accelerating the Future of Nanotherapeutics' scheduled for December 19, 2024, at 9:00 AM ET / 3:00 PM CET. The event will showcase the company's Curadigm Nanoprimer Platform, a new nanotherapeutic technology designed to enhance intravenously-administered therapeutics.
The presentation will feature CEO Laurent Lévy and Curadigm Head Matthieu Germain, followed by a panel discussion with experts including Margaret A. Liu, a globally recognized authority in gene therapy, vaccines, and immunotherapy. The company confirms its lead program is proceeding as planned while exploring new nanotherapeutic technologies to improve patient treatment outcomes.
Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of November 30, 2024. The company has 47,426,851 shares outstanding, with 49,202,229 theoretical voting rights and 49,180,111 exercisable voting rights. Nanobiotix, founded in 2003 and headquartered in Paris, is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix announced completion of Phase 1 study evaluating RT-activated NBTXR3 in pancreatic cancer patients. The study showed encouraging results with 23 months median Overall Survival from diagnosis in 22 patients with locally advanced or borderline resectable pancreatic cancer, compared to 19.2 months historical control at MD Anderson.
The treatment was well-tolerated, and investigators concluded the favorable safety profile and oncologic outcomes warrant further evaluation in a randomized trial. The FDA approved a protocol amendment to launch a new cohort studying NBTXR3 combined with standard-of-care concurrent chemotherapy, with recruitment currently ongoing. Full data presentation is expected at a medical congress in first half of 2025.
Nanobiotix has released its monthly report on voting rights and share capital as of October 31, 2024. The company reported 47,426,851 shares outstanding, with 49,201,086 theoretical voting rights and 49,178,968 exercisable voting rights. The company's shares are listed on both Euronext Paris and Nasdaq under the ticker symbol NBTX.
Nanobiotix provided its Q3 2024 update, highlighting key operational progress. The company transferred US sponsorship of the global Phase 3 NANORAY-312 head and neck cancer study to Janssen, marking a important step toward potential NBTXR3 regulatory submission. The company reported €53.2 million in cash and cash equivalents as of September 30, 2024, with runway into Q4 2025.
Updates on NBTXR3 in pancreatic cancer and lung cancer studies with MD Anderson are expected in Q4 2024 and 1H 2025, respectively. The company strengthened its Supervisory Board with Dr. Margaret A. Liu and Ms. Anat Naschitz as board observers. An interim analysis for NANORAY-312 is anticipated after reaching required events and last patient recruitment in 1H 2026.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announces participation in three major healthcare conferences in November 2024. The company will engage in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference (Nov 11, Boston), the Stifel Healthcare Conference (Nov 18, New York), and the Jefferies London Healthcare Conference (Nov 20, London). Company executives Laurent Levy (CEO) and Bart van Rhijn (CFO) will present at these events. All sessions will be webcast live and available for replay on the company's investor relations website.
Nanobiotix (NBTX), a company listed on Euronext Paris and Nasdaq, has released its monthly report on voting rights and share capital as of September 30, 2024. This disclosure is in compliance with French regulatory requirements. The company reported 47,426,851 shares outstanding, with 49,200,752 total theoretical voting rights and 49,178,634 total exercisable voting rights.
Nanobiotix, traded under the ticker NANO:FP on Bloomberg and NANO.PA on Reuters, is committed to regular updates on its capital structure. The company will publish new figures monthly if there are changes from previously disclosed information, adhering to transparency standards set by French financial authorities.
Nanobiotix (NASDAQ: NBTX) provided a business update and reported half-year 2024 financial results. Key highlights include:
1. Favorable safety profile and tumor response for RT-NBTXR3 followed by anti-PD-1 in head and neck cancer patients.
2. Several clinical milestones expected in the next 12-18 months for pancreatic, head and neck, esophageal, and lung cancers.
3. €66.3 million in cash and cash equivalents as of June 30, 2024, with runway extended into Q4 2025.
4. Revenue increased to €9.3 million, up from €3.3 million in H1 2023.
5. Net loss of €21.9 million, or €0.46 per share, compared to €28.1 million, or €0.80 per share in H1 2023.
6. Ongoing global Phase 3 trial (NANORAY-312) for head and neck cancer with interim analysis expected by 1H2026.
Nanobiotix (Euronext: NANO – NASDAQ: NBTX) has nominated Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board. Dr. Liu, CEO of PAX Therapeutics, is a global expert in vaccines, gene therapy, and cancer immunotherapy. Ms. Naschitz, co-founder of OrbiMed Israel, is a proven life science investor and entrepreneur.
These additions aim to equip Nanobiotix for sustainable long-term growth. Dr. Liu brings experience in academia, pharmaceuticals, biotechnology, and public policy. Ms. Naschitz offers expertise in capital utilization for disruptive innovation. Both nominees have extensive global experience in the biopharmaceutical industry, which is expected to reinforce Nanobiotix's strategic initiatives in oncology for NBTXR3 and expand development opportunities beyond it.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will feature a fireside chat with company management on Wednesday, September 11, 2024, at 9:30 AM EDT / 3:30 PM CEST in New York, NY.
Presenters include Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer. The fireside chat will be webcast live from the company's website, with a replay available after the event. Nanobiotix is known for pioneering physics-based approaches to expand treatment possibilities for cancer patients.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
